- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
ALK Antibody (N-term)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP11211a | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP11211a-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
ALK Antibody (N-term) - Product info | |
| Application | WB
|
| Primary Accession | Q9UM73 |
| Other Accession | P97793, NP_004295 |
| Reactivity | Human |
| Predicted | Mouse |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 176442 Da |
ALK Antibody (N-term) - Additional info | |
| Gene ID 238 | |
| Other Names ALK; ALK tyrosine kinase receptor; Anaplastic lymphoma kinase; CD_antigen=CD246; Flags: Precursor | |
| Target/Specificity This ALK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 176-205 amino acids from the N-terminal region of human ALK. | |
| Dilution WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions ALK Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
ALK Antibody (N-term) - Protein Information | |
| Name ALK | |
| Function Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK | |
| Cellular Location Cell membrane; Single-pass type I membrane protein. Note=Membrane attachment was crucial for promotion of neuron-like differentiation and cell proliferation arrest through specific activation of the MAP kinase pathway | |
| Tissue Location Expressed in brain and CNS. Also expressed in the small intestine and testis, but not in normal lymphoid cells | |
ALK Antibody (N-term) - Related products
AP11211a: ALK Antibody (N-term)
AP11629c: ALK Antibody (C-term Y1604)
AP3756a: Phospho-ALK- Y1282/1283 Antibody
AP3756b: Phospho-ALK- Y1282 Antibody
AP3757a: Phospho-ALK- Y1278 Antibody
AP3760a: Phospho-ALK-Y1604 Antibody
AP3761a: Phospho-ALK-Y1586 Antibody
ALK Antibody (N-term) - Application data
-
ALK Antibody (N-term) (Cat. #AP11211a) western blot analysis in MDA-MB231 cell line lysates (35ug/lane).This demonstrates the ALK antibody detected the ALK protein (arrow).
ALK Antibody (N-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
The 2;5 chromosomal translocation is frequently associated with anaplastic large cell lymphomas (ALCLs). The translocation creates a fusion gene consisting of the ALK (anaplastic lymphoma kinase) gene and the nucleophosmin (NPM) gene: the 3' half of ALK, derived from chromosome 2, is fused to the 5' portion of NPM from chromosome 5. A recent study shows that the product of the NPM-ALK fusion gene is oncogenic. The deduced amino acid sequences reveal that ALK is a novel receptor protein-tyrosine kinase having a putative transmembrane domain and an extracellular domain. These sequences are absent in the product of the transforming NPM-ALK gene. ALK shows the greatest sequence similarity to LTK (leukocyte tyrosine kinase). ALK plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system.
REFERENCES
Ardini, E., et al. Cancer Lett. 299(2):81-94(2010) Ohira, M., et al. Cancer Sci. 101(11):2295-2301(2010) Merkel, O., et al. Proc. Natl. Acad. Sci. U.S.A. 107(37):16228-16233(2010) De Brouwer, S., et al. Clin. Cancer Res. 16(17):4353-4362(2010) Bossi, R.T., et al. Biochemistry 49(32):6813-6825(2010)
